Hematology

The 2026 EHA Congress, convening in Stockholm next week, will bring the global hematology community together for 4 days of science, debate, and discovery.

CLL’s intrinsic immune dysfunction spans humoral, cellular, and innate defects, persisting even with targeted therapy.

FDA decisions in May 2026 included 5 major oncology approvals, including first-in-class therapies for breast cancer, AML, MCL, and NMIBC.

Ajai Chari, MD, unpacks resistance mechanisms, treatment sequencing, and why myeloma’s future may be brighter than anyone predicted.

Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

Data over 17 years from a new analysis contrast prior research in this area, but remain promising on the use of intravenous immunoglobulin in this hematologic cancer.

Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.

ASCO highlights MorningSun results: subcutaneous mosunetuzumab offers a chemotherapy-free option for elderly patients with DLBCL, improving quality of life beyond R-CHOP.

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK inhibitors and venetoclax regimens.

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.

New review details biologic, psychosocial, and treatment barriers shaping outcomes in AYA acute lymphoblastic leukemia (ALL).

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know about managing infections and CRS.

Adam Kittai, MD, weighs the favorable safety profile of acalabrutinib plus venetoclax against lingering unknowns on long-term efficacy and high-risk patients.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

Researchers found major differences between smoldering myeloma risk tools, raising concerns about overtreatment and defining “high risk.”

Efficacy and safety top the list for patients and physicians making R/R CLL treatment decisions, yet fewer than 1 in 3 patients felt their doctor fully answered their questions.

Nicholas Richardson, DO, MPH, discussed the implications of the FDA’s January draft guidance proposing MRD-negative complete response as a primary end point for accelerated approval in multiple myeloma.

Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.